Asian Growth Companies With High Insider Ownership May 2025

As the global market responds positively to the recent U.S.-China tariff pause, Asian markets are experiencing a renewed sense of optimism, with stock indices showing signs of recovery. In this environment, growth companies with high insider ownership in Asia present intriguing opportunities for investors seeking alignment between management and shareholder interests.

Top 10 Growth Companies With High Insider Ownership In Asia

Click here to see the full list of 621 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

APT Medical (SHSE:688617)

Simply Wall St Growth Rating: ★★★★★★

Overview: APT Medical Inc. focuses on the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China with a market cap of CN¥40.76 billion.

Operations: The company's revenue segment consists of medical products, generating CN¥2.17 billion.

Insider Ownership: 22%

Revenue Growth Forecast: 25.6% p.a.

APT Medical's earnings grew by 25.4% last year, with future earnings expected to grow significantly at 26.6% per year, outpacing the CN market's projected growth. Revenue is also forecast to increase rapidly at 25.6% annually. The company trades at a substantial discount of 44.5% below its estimated fair value and boasts a high forecasted Return on Equity of 28.8%. Recent quarterly results show strong performance with sales reaching CNY 564.28 million, up from CNY 455.33 million the previous year, and net income rising to CNY 183.15 million from CNY 140.14 million.

• Click to explore a detailed breakdown of our findings in APT Medical's earnings growth report.
• In light of our recent valuation report, it seems possible that APT Medical is trading behind its estimated value.

Anhui Huaheng Biotechnology (SHSE:688639)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Anhui Huaheng Biotechnology Co., Ltd. is involved in the development, production, and sale of amino acids and other organic acids both in China and internationally, with a market cap of CN¥7.87 billion.

Operations: The company's revenue is primarily derived from its Bio Manufacturing Industry segment, amounting to CN¥2.36 billion.

Insider Ownership: 30.1%

Revenue Growth Forecast: 21% p.a.

Anhui Huaheng Biotechnology is poised for significant growth, with earnings projected to increase by over 42% annually, surpassing the Chinese market's average. Revenue is also expected to grow at a robust 21% per year. However, recent financials show a decline in net income from CNY 86.57 million to CNY 51.1 million year-over-year despite sales rising to CNY 687.06 million from CNY 500.78 million, indicating challenges in maintaining profit margins amidst expansion efforts.

• Get an in-depth perspective on Anhui Huaheng Biotechnology's performance by reading our analyst estimates report here.
• According our valuation report, there's an indication that Anhui Huaheng Biotechnology's share price might be on the expensive side.

Shenzhen Noposion Crop Science (SZSE:002215)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shenzhen Noposion Crop Science Co., Ltd. engages in the research, development, production, and sale of agricultural inputs both in China and internationally, with a market cap of CN¥10.58 billion.

Operations: The company's revenue is primarily derived from the research, development, production, and sale of agricultural inputs both domestically and internationally.

Insider Ownership: 29.6%

Revenue Growth Forecast: 14.9% p.a.

Shenzhen Noposion Crop Science demonstrates promising growth potential, with earnings expected to rise significantly at 25.1% annually, outpacing the Chinese market. Despite high debt levels and a dividend yield of 3.28% not fully covered by free cash flows, its revenue is forecast to grow faster than the market average. Recent financials reveal strong performance with Q1 2025 net income increasing to CNY 626.93 million from CNY 454.31 million year-over-year, indicating robust operational growth despite financial constraints.

• Click here and access our complete growth analysis report to understand the dynamics of Shenzhen Noposion Crop Science.
• Our comprehensive valuation report raises the possibility that Shenzhen Noposion Crop Science is priced lower than what may be justified by its financials.

Make It Happen

• Unlock more gems! Our Fast Growing Asian Companies With High Insider Ownership screener has unearthed 618 more companies for you to explore.Click here to unveil our expertly curated list of 621 Fast Growing Asian Companies With High Insider Ownership.
• Seeking Other Investments? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com